Vivoryon Therapeutics AG (GB:0R3M) has released an update.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Vivoryon Therapeutics N.V. has announced promising new data showing that its drug varoglutamstat significantly improves kidney function in diabetic patients. In addition to kidney benefits, the treatment also exhibited potential health improvements including weight loss and lower blood pressure without notable adverse events. The company is now planning to advance the drug into a Phase 2 clinical study for diabetic kidney disease.
For further insights into GB:0R3M stock, check out TipRanks’ Stock Analysis page.